• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Press Media Release

press release distribution

  • Submit a Press Release
  • Market Wire
  • Make a Contribution
  • About
    • Template for press/media release
  • Contact

New Study Shows That Hydroxychloroquine Saves Lives, States Association of American Physicians & Surgeons (AAPS)

July 7, 2020 By admin Leave a Comment

A just published peer-reviewed study from Henry Ford Health System showed that the death rate of hospitalized patients who received hydroxychloroquine (HCQ) was cut in half, and there were no serious heart abnormalities.

The Association of American Physicians & Surgeons (AAPS) stated that these results should encourage widespread early use of this long-established drug to fight COVID-19.

“HCQ impressively improved survival. In contrast, the government-favored drug remdesivir has only been shown to decrease survivors’ hospital stay by four days, with no demonstrable improvement in survival,” notes AAPS.

Even before the Henry Ford study, there was substantial evidence of HCQ benefit, especially when used very early in out-patients in combination with zinc, in a compilation of studies prior to April 20, a more recent compilation, and a preprint by Dr. Vladimir Zelenko and colleagues released July 3. Yale epidemiologist Harvey Risch, M.D., wrote that HCQ is an “early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis.”

Based on flawed studies and pronouncements from government officials, doctors have hesitated to use HCQ because of claimed lack of proof of efficacy, or purported danger of cardiac arrhythmias. Two studies, in Lancet and NEJM, were retracted because of questionable data. A study from Brazil, published in JAMA, is under investigation because researchers were giving patients lethal doses of chloroquine.

Researchers have been using HCQ too late, when patients may already have COVID-caused heart damage, and overdosing patients, states AAPS.

“If HCQ saves half the patients who would have died in hospital, then withholding HCQ is causing tens of thousands of preventable deaths,” states AAPS.

“The federal government has agreed to buy 500,000 doses of remdesivir at more than $3,000 per course of treatment, without proof that it will save lives. Why won’t it release HCQ, which costs about $20 per course of treatment, from the Strategic National Stockpile, and stop prohibiting or discouraging its use?” asks AAPS.

“Patients are dying needlessly every day.”

AAPS has filed for a preliminary injunction to stop interference by the FDA with patient access to HCQ, and to prevent the government from wasting the HCQ which was donated to its stockpile. This lawsuit is pending in federal court in Grand Rapids, Michigan, AAPS v. FDA, et al., 20-cv-493.

The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.

SOURCE Association of American Physicians and Surgeons (AAPS)

HOME

Filed Under: Press Release

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • The Role of Forests in Climate Change Mitigation
  • U.S. Department of State, Bezos Earth Fund, and Rockefeller Foundation Announce Next Steps on Energy Transition Accelerator
  • Social Media Digest
  • COVID-19 Claims 2,000 Lives Per Week; 3 Critical Things Everyone Should Know
  • Economic Uncertainty Rising, 83% of Marketing Leaders to Prioritize Investments in Operational Efficiency and Hiring in 2023
  • PXEF.com adds new AI painting to art gallery: “Rich girl, poor girl in the swimming pool”
  • Market Research Media releases new market research report on the U.S. government market for low-code/no-code software
  • XRY, the MSAB extraction solution, comes with new features centered on ensuring the chain of custody of digital evidence
  • Ultisim Announces Advisory Board
  • Exclusive.org Announces Sale of Exclusive Domains

Media Partners

  • VPNW.com
  • OPINT
  • Digital Market
How to have a healthy work-life balance
What’s your biggest challenge as a creator?
Salary transparency: is it good or bad thing?
What is a personal experience map?
Adaptability Paradox
PNSF Director visits the world’s largest experimental earthquake infrastructure facility
Domains of the Day: AfricanInvesting.com
Why the U.S. economy needs increase in population
Market Research Digest
CrowdStreet and Juniper Square Partner to Usher in the Next Chapter of Digital Transformation for the Commercial Real Estate Industry
Ethereum and IPFS gateways are publicly available to all Cloudflare customers
A license for a Bloomberg Terminal costs $24,000 per year, OpenBB is free
The 10th Global Blockchain Congress, July 11-12, 2022, Vietnam, Hanoi
Deloitte: Holiday Retail Sales Expected to Increase 7-9%
Top cryptocurrencies are Bitcoin, Ethereum, Bitcoin Cash, DAI, Litecoin and USD Coin

Media Partners

  • Media Instances
  • PXEF.com
  • S3H.com
The man in concrete wall
Phoenician artifacts provide a fascinating window into the history and culture of this ancient civilization
People in the Middle Ages bathed regularly, contrary to popular myth
A tale of a person who can’t get home for Christmas due to travel chaos in the UK
Manchester Chinese Consulate staff dragging a Hong Kong protester onto the grounds of the Consulate to bash him
Geisha in the bath
65 Percent of Paycheck-to-Paycheck Consumers Experienced a Financially Stressful Event in the Past Three Years
Halloween party
What does it take to be a digital nomad
Photographic history of America
Technology Events
Why are so many tech companies laying people off in the period of high inflation?
Student debt is disproportionately held by the richer half of the population
5G Brings New Threats and Opportunities to Cybersecurity Landscape
The world has seen a disturbing trend in recent years of cooperation giving way to competition and ultimately conflict

Copyright © 2022 PressMediaRelease.com

Sponsored by Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT